Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Jazz Pharma Plc (NQ: JAZZ )

111.76 +0.21 (+0.19%)
Streaming Delayed Price Updated: 11:24 AM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Jazz Pharma Plc

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. 
Via Benzinga
Topics Cannabis
Exposures Cannabis
7 Cannabis Stocks to Buy for a Smoking-Hot 2024
Ignite your portfolio with these seven sizzling cannabis stocks. From industry leaders to innovative upstarts. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
The 7 Top-Selling Cannabis Companies Ranked by Revenue: Which Weed Stocks to Buy?
These top cannabis stocks by revenue are among the world's best sellers, making them prime investment opportunities to capture legal changes. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
Demystifying Jazz Pharmaceuticals: Insights From 15 Analyst Reviews
Via Benzinga
JAZZ Stock Earnings: Jazz Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024
JAZZ stock results show that Jazz Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views
Via Benzinga
The Analyst Landscape: 12 Takes On Jazz Pharmaceuticals
Via Benzinga
Demystifying Jazz Pharmaceuticals: Insights From 4 Analyst Reviews
Via Benzinga
3 No-Brainer Stocks to Buy With $300 Right Now
A modest amount of money can go a long way on Wall Street when it's put to work in time-tested businesses with well-defined catalysts. 
Via The Motley Fool
How To Make Your Cannabis Business More Attractive For Investors In 2024: Advice On Financial Health & Innovation
Via Benzinga
Topics Cannabis
Exposures Cannabis
HC Wainwright & Co. Maintains Buy Rating for Jazz Pharmaceuticals: Here's What You Need To Know
Via Benzinga
7 Biotech Stocks to Buy as Sector Rotation Ramps Up
With digital innovation possibly getting overextended, now’s the time to consider biotech stocks for an incoming rotation. 
Via InvestorPlace
Time Is Still The Enemy, Says Mom Who Moved Mountains For Her Epileptic Daughter & Still Advocates For Millions Of CBD Users
Via Benzinga
Evaluating Jazz Pharmaceuticals: Insights From 7 Financial Analysts
Via Benzinga
Decoding 6 Analyst Evaluations For Jazz Pharmaceuticals
Via Benzinga
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Although the health innovation space can be a risky environment, undervalued biotech stocks can take some of the edge off. 
Via InvestorPlace
4 Exhilarating Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
The Nasdaq Composite is the only major stock index that hasn't put the 2022 bear market in the rearview mirror. For patient investors, it means bargains still abound. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
3 Cannabis Stocks That Could Be Multibaggers in the Making: February Edition
Don’t miss out, as the following cannabis stocks are severely undervalued and are set to increase sales and make huge profits in 2024. 
Via InvestorPlace
Topics Cannabis
Exposures Cannabis
The Queen Of Marijuana Investing Used Psychology To Launch Her Successful Cannabis Investment Fund
Via Benzinga
Topics Cannabis
Exposures Cannabis
3 Biotech Stocks to Buy on the Dip: February 2024
Here are three biotech stocks to buy that are trading at prices that may not account for potential breakthrough opportunities 
Via InvestorPlace
3 Strong Buy Biotech Stocks to Add to Your February Must-Watch List
These biotech stocks offer investors huge potential in the future. Investors may want to consider these equities to enter the industry. 
Via InvestorPlace
4 Eye-Catching Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
The growth-fueled Nasdaq Composite remains nearly 6% below its all-time high, which means amazing deals can still be found. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Wall Street Favorites: 3 Biotech Stocks With Strong Buy Ratings for January 2024
Biotech stocks are warming up in January and look to continue upward in 2024 as the economy improves. Here are three to check out. 
Via InvestorPlace
Topics Economy
Exposures Economy
Japanese University Will Research Marijuana's Medical Uses In First-Of-Its-Kind Collaboration With Australian Company
Via Benzinga
Topics Cannabis
Exposures Cannabis
2 Incredible Growth Stocks That Are Screaming Buys for 2024
These healthcare businesses are compelling buys for very different reasons. 
Via The Motley Fool
4 Remarkable Growth Stocks You'll Regret Not Buying in the Wake of the Nasdaq Bear Market Dip
The growth-fueled Nasdaq Composite remains 7% below its all-time high, which means bargains can still be found. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
US Stocks Set To Open Weaker As Traders Eye Key Main Street Events: Analyst Sees Buying Opportunity On 'Stunning' Earnings Expectations
Several market-moving catalysts, including the release of the Fed minutes, a Federal Reserve speech, and JOLTS data, could influence the day's market movement. 
Via Benzinga
Topics Economy
Exposures Interest Rates
7 Growth Stocks Poised to Thrive in a Post-Fed Pivot World
If the Federal Reserve loosens the monetary spigot, these companies could represent the growth stocks to buy now. 
Via InvestorPlace
Topics Economy
Exposures Interest Rates
Jazz Pharmaceuticals' Post-Traumatic Stress Disorder Drug Disappoints In Mid-Stage Study
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced top-line results from the Phase 2 trial of JZP150, an investigational small molecule selective fatty acid amide hydrolase (FAAH) inhibitor, on efficacy... 
Via Benzinga
3 No-Brainer Stocks to Buy With $500 Right Now
You don't need a mountain of cash to build wealth on Wall Street. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.